Roth Capital Partners has reestablished estimates, a ‘buy” rating, and $17 price target for Aduro Biotech (NASDAQ:ADRO) based on a sum-of-parts, probability-adjusted net present value analysis. The stock closed at $11 on March 6.Read More
Common shares of 3D Signatures (TSX-V:DXD) have started trading on the OTCQB Venture Market in the U.S. under the symbol, TDSGF, and on the Frankfurt Stock Exchange (FSE) in Germany under the symbol, 3D0.Read More
BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral,” with a price target of $10, after the company reported third quarter results. The stock closed at $7.13 on Wednesday.
“When we downgraded shares at $9, our view was that a fair amount of good news had been priced into the stock – less draconian cuts to reimbursement, synergy capture of Clarient and continued share gains,” writes analyst Dr. Sean Lavin.Read More
Leerink Partners has downgraded Epirus Biopharmaceuticals (NASDAQ:PRS) to “market perform” from “outperform” and slashed its price target to 75 cents from $10. The stock closed at 78 cents on Friday.
Analyst Jason Gerberry writes that the downgrades follows a change in senior management, suspension of Eprius’ lead program and a strategic change to prioritize the company’s rare disease biosimilars, which are currently in preclinical development.Read More